Stock Market News
Indivior settles with Par over delayed generic Suboxone
Indivior has reached a settlement to resolve patent litigation it had filed over its Suboxone treatment for opioid addiction against Par Pharmaceutical.
In 2016, a US district court ruled that Indivior's asserted claims of its US Patent No. 8,017,150, which is set to expire in 2023, were valid but not infringed by a generic equivalent for which Par had applied for regulatory permission, with a similar product also having been submitted by Watson Pharmaceutical's Actavis generic drug business.
The FTSE 250 company said on Monday that as part of its settlement, Par would be allowed to begin selling a generic version of Suboxone film from 1 January 2023.
"We continue to seek greater certainty for Indivior, but on terms that adequately reflect the strength of our intellectual property," said Indivior chief executive Shaun Thaxter, adding that three new Orange Book patents have been asserted against the remaining companies to have filed Abbreviated New Drug Application with the US regulator to make generic Suboxone.
The remaining three ANDA filers are Teva, Actavis and Dr Reddy's.
In 2016, a US district court ruled that Indivior's asserted claims of its US Patent No. 8,017,150, which is set to expire in 2023, were valid but not infringed by a generic equivalent for which Par had applied for regulatory permission, with a similar product also having been submitted by Watson Pharmaceutical's Actavis generic drug business.
The FTSE 250 company said on Monday that as part of its settlement, Par would be allowed to begin selling a generic version of Suboxone film from 1 January 2023.
"We continue to seek greater certainty for Indivior, but on terms that adequately reflect the strength of our intellectual property," said Indivior chief executive Shaun Thaxter, adding that three new Orange Book patents have been asserted against the remaining companies to have filed Abbreviated New Drug Application with the US regulator to make generic Suboxone.
The remaining three ANDA filers are Teva, Actavis and Dr Reddy's.
Related share prices |
---|
Indivior (INDV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price